Stockreport

ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF Anktiva has been approved for BCG-unresponsive non-muscle invasive bladder cancer, with promising early commercial progress. The treatment faces strong competition fr [Read more]